The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.

Providing continuing support for the SHDSL product portfolio NEWBURYPORT, Mass.–(BUSINESS WIRE)–#MaxLinear–MaxLinear, Inc., an industry leader in high-performance analog and mixed-signal integrated ...

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for ...

Cloudflare, Inc. , the leading connectivity cloud company, today announced that it is making several critical security tools free, including access to its comprehensive Zero Trust platform, Cloudflare ...